Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antisense of IGF2R non-protein coding RNA (AIRN) is a long non-coding RNA transcribed from the paternal allele at the IGF2R locus. It acts as a cis-regulatory RNA essential for genomic imprinting, specifically mediating the transcriptional silencing of the paternal IGF2R, SLC22A2, and SLC22A3 genes through epigenetic mechanisms. In mice, AIRN is expressed from a differentially methylated region (DMR) in intron 2 of IGF2R and overlaps the IGF2R promoter; its transcriptional activity, rather than the RNA product itself, silences the paternal allele by interfering with RNA polymerase II binding. In the placenta, AIRN can also recruit histone methyltransferases for silencing additional genes. Besides its canonical imprinting role, recent evidence highlights that AIRN interacts with the RNA-binding protein IGF2BP2 and modulates the translation of various transcripts, influencing cell survival and migration in cardiomyocytes. AIRN is evolutionarily conserved and one of the best-characterized lncRNAs regulating imprinting and gene expression at the chromatin and translational levels in mammals[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antisense of IGF2R non-protein coding RNA (AIRN).